Dapagliflozin Improves Body Fat Patterning, and Hepatic and Pancreatic Fat in Patients With Type 2 Diabetes in North India.

Abstract

CONTEXT:

Excess hepatic and pancreatic fat may contribute to hyperglycemia.

OBJECTIVE:

The objective of this study was to examine the effect of dapagliflozin (an SGLT2 inhibitor) on anthropometric profile, liver, and pancreatic fat in patients with type 2 diabetes mellitus (T2DM).

METHODS:

This is an observational interventional paired study design without a control group. Patients (n = 30) were given dapagliflozin 10 mg/day (on top of stable dose of metformin and/or sulfonylureas) for 120 days. Changes in anthropometry (circumferences and skinfold thickness), surrogate markers of insulin resistance, body composition, liver, and pancreatic fat (as measured by magnetic resonance imaging (MRI)-derived proton density fat fraction [FF]) were evaluated.

RESULTS:

After 120 days of treatment with dapagliflozin, a statistically significant reduction in weight, body mass index (BMI), body fat, circumferences, and all skinfold thickness was seen. A statistically significant reduction in blood glucose, glycated hemoglobin A1c, hepatic transaminases, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR), and postprandial C-peptide was noted, while HOMA-β, postprandial insulin sensitivity, and fasting adiponectin were statistically significantly increased. There was no change in lean body mass. Compared to baseline there was a statistically significant decrease in mean liver FF (from 15.2% to 10.1%, P < .0001) and mean pancreatic FF (from 7.5% to 5.99%, P < .0083). Reduction in liver fat was statistically significant after adjustment for change in body weight.

CONCLUSION:

Dapagliflozin, after 120 days of use, reduced pancreatic and liver fat and increased insulin sensitivity in Asian Indian patients with T2DM.

• Authors: Amerta Ghosh, Koel Dutta, Surya Prakash Bhatt, Ritesh Gupta, Kanika Tyagi, Irshad Ahmad Ansari, Vasantha Kumar Venugopal, Harsh Mahajan, Ravindra Mohan Pandey, Shivam Pandey, Anoop Misra
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 107 Issue 6 Pg. e2267-e2275 (05 17 2022) ISSN: 1945-7197 [Electronic] United States
• PMID: 35263436 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
• Copyright: © The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Benzhydryl Compounds
• Blood Glucose
• Glucosides
• Hypoglycemic Agents
• Insulin
• dapagliflozin

Topics

• Adipose Tissue (diagnostic imaging)
• Benzhydryl Compounds
• Blood Glucose
• Body Fat Distribution
• Diabetes Mellitus, Type 2 (drug therapy)
• Glucosides
• Humans
• Hypoglycemic Agents (therapeutic use)
• Insulin (therapeutic use)
• Insulin Resistance
• Liver (diagnostic imaging)